Conserved retinoblastoma protein-binding motif in human cytomegalovirus UL97 kinase minimally impacts viral replication but affects susceptibility to maribavir
- Rachel B Gill†1, 3,
- Samuel L Frederick†1,
- Caroll B Hartline1,
- Sunwen Chou2 and
- Mark N Prichard1Email author
© Gill et al; licensee BioMed Central Ltd. 2009
Received: 29 December 2008
Accepted: 21 January 2009
Published: 21 January 2009
The UL97 kinase has been shown to phosphorylate and inactivate the retinoblastoma protein (Rb) and has three consensus Rb-binding motifs that might contribute to this activity. Recombinant viruses containing mutations in the Rb-binding motifs generally replicated well in human foreskin fibroblasts with only a slight delay in replication kinetics. Their susceptibility to the specific UL97 kinase inhibitor, maribavir, was also examined. Mutation of the amino terminal motif, which is involved in the inactivation of Rb, also renders the virus hypersensitive to the drug and suggests that the motif may play a role in its mechanism of action.
Human cytomegalovirus (HCMV) is a ubiquitous virus that can be problematic in immunocompromised populations, including individuals with AIDS or recipients of allograft transplants. It is the most common congenital infection in the United States  and sequela include permanent neurological deficits, including hearing loss [2, 3]. Ganciclovir (GCV), foscarnet and cidofovir (CDV) have all been approved for the treatment of HCMV infection, but each drug is associated with dose-limiting toxicities . The benzimidazole L-riboside maribavir (MBV) is currently in Phase III clinical trials for the treatment of HCMV infections and inhibits viral replication by a distinct mechanism involving the direct inhibition of UL97 kinase activity [4–7]. While this drug clearly inhibits the enzymatic activity of the UL97 kinase in infected cells, the consequences of its inhibition are complex and incompletely understood as the kinase affects many cellular and viral processes.
The UL97 serine/threonine kinase is expressed early in infection and is found within the tegument of infectious virions [8, 9]. Although the kinase is not required for viral replication, null mutants exhibit severe replication deficits , which is consistent with the inhibitory effects of MBV . This enzyme has been shown to phosphorylate viral proteins including itself, ppUL44 and pp65 [11–13], as well as the large subunit of RNA polymerase II, eukaryotic elongation factor 1delta, P32 and lamins A/C [14–16]. The tumor suppressor retinoblastoma (Rb) has also been shown to be hyperphosphorylated in cells infected with HCMV , and this phosphorylation is dependent on UL97 kinase activity . This report also showed that mutations in either the essential lysine (K355) or the conserved LxCxE Rb-binding motif in the amino terminus of pUL97 reduced the inactivation of Rb . A separate study showed that the kinase phosphorylated Rb directly and did not require other proteins . This activity is intriguing since Rb is also targeted by many viruses, including human papilloma virus, simian virus 40, and adenovirus . However, the interaction seems to be finely-tuned between HCMV and the cell and does not appear to result in an oncogenic phenotype exhibited by other viruses which target Rb.
Rb belongs to the family of pocket proteins which prevent the progression of the cell through the G1/S checkpoint by binding to and suppressing the function of the transcription factor E2F; hyperphosphorylation of Rb causes it to release E2F which activates key steps in the cell cycle . The inactivation of Rb by the kinase is presumed to modify cell checkpoint protein expression and induce the expression of cellular proteins required for viral infection, but its impact on viral replication has not been established. The UL97 gene product contains three consensus binding sequences for Rb [18, 19]; disruption of the essential lysine or the amino terminal Rb-binding motif (LxCxE) reduces the Rb phosphorylation seen in HCMV wild type (wt) inoculated cells . Therefore, we hypothesized that viruses with disrupted Rb-binding sites in the UL97 kinase might have an impaired replication phenotype or altered susceptibility to antiviral drugs.
A second set of viruses was constructed that contained a secreted alkaline phosphatase (SEAP)-expression cassette at US6 (T2211) . The LxCxE motif was disrupted with a C151 deletion (T3038) and pUL97 was truncated at codon 536 to yield a null mutant (T2266). Replication of these viruses was assessed in human embryonic lung (HEL) cells infected at an MOI of 0.01–0.03 PFU/cell, and SEAP supernatant activity was determined with a chemiluminescent substrate. No detectable differences were observed between the wt virus (T2211) and the UL97 ΔC151 virus (T3038) [Figure 1D]. The UL97-truncated virus (T2266) replicated poorly and had growth characteristics similar to those of RC314, and confirmed that defects in kinase activity could be detected in these studies. Results from both experiments indicated that mutation of the LxCxE motif did not severely impact virus replication. The minor delay in virus replication was not apparent in the T3038 and is likely related to assay differences. We conclude that the disruption of each of the Rb binding motifs individually or of the two amino terminal motifs in tandem has only minor effects on viral replication in cell culture. However, we cannot exclude the possibility that the disruption of all three may impact growth or that replication may be more compromised in other systems.
UL97 recombinant sensitivity to Maribavir
0.37 ± 0.03
0.15 ± 0.05
3.6 ± 3
14 ± 5
0.1 ± 0.07
38 ± 10
0.22 ± 0.08c
0.18 ± 0.04
2.8 ± 0.9
0.39 ± 0.2
0.22 ± 0.1
4.2 ± 2
0.3 ± 0.1
0.18 ± 0.1
3.2 ± 3
0.5 ± 0.2
0.08 ± 0.05
3.5 ± 3
0.100 ± 0.008
0.23 ± 0.01
1.16 ± 0.18
0.031 ± 0.002c
0.27 ± 0.01
1.03 ± 0.13
To confirm these data, the susceptibility of the SEAP-reporter viruses was also evaluated against GCV and MBV using SEAP activity as a surrogate marker of viral replication. Data were obtained by infecting confluent HEL fibroblasts at an MOI of 0.01–0.03 PFU/cell and SEAP activity in the supernatant was determined 6 days following infection . MBV sensitivity data are the average of 8 determinations from 3 independent experiments for the T3038 and T2211 viruses tested simultaneously; the GCV EC50 values are consistent with historical data and are shown as the average of triplicate determinations. These data confirmed that the disruption of the amino terminal Rb-binding domain resulted in significantly increased sensitivity to MBV. While the EC50 values differ between the plaque reduction assays and the SEAP assays, both assays are consistent in that they both show that disruption of the amino terminal Rb binding motif results in increased susceptibility to MBV. These suggest that the mechanism of action of MBV may involve the LxCxE Rb binding motif and is consistent with the idea that the prevention of Rb inactivation by MBV might be an important aspect of its mechanism of action.
Disruption of the central cysteines in the UL97 Rb-binding motifs does not result in a severe replication deficiency reminiscent of kinase null viruses, but rather results in a very modest delay in viral replication. This might suggest that the inactivation of Rb is not a crucial function in HFF or HEL cells and that it may be important only in vivo. Alternatively, it is possible that the motifs are redundant and all of them must be deleted to impact replicative ability of the virus. Nevertheless, the C151G mutation in the RC295 virus and the C151 deletion in the T3038 virus clearly conferred hypersensitivity to MBV when compared to their isogenic controls. While potential mechanisms for this are unclear, it indicates that mechanism of action of the drug is related to the function of the amino terminal Rb-binding motif at some level. Additional experiments will be required to assess the potential impact of double and triple mutants. Nonetheless, these findings offer insight into a new aspect of MBV activity and additional studies with the inhibitor together with genetic studies will help define the function of the kinase in viral infection.
secreted alkaline phosphatise
multiplicity of infection
human embryonic lung fibroblasts
National Institute of Allergy and Infectious Diseases
Open reading frame
human foreskin fibroblasts
We thank Gail Marousek for expert technical assistance. This work was supported by the Department of Veterans Affairs research funds and Public Health Service contract NO1-AI-30049 from NIAID, NIH, Bethesda, MD.
- Cytomegalovirus (CMV)[http://www.cdc.gov/cmv/index.htm]
- Boppana SB, Fowler KB, Pass RF, Rivera LB, Bradford RD, Lakeman FD, Britt WJ: Congenital cytomegalovirus infection: association between virus burden in infancy and hearing loss. J Pediatr 2005, 146: 817-823. 10.1016/j.jpeds.2005.01.059View ArticlePubMedGoogle Scholar
- Fowler KB, Boppana SB: Congenital cytomegalovirus (CMV) infection and hearing deficit. J Clin Virol 2006, 35: 226-231. 10.1016/j.jcv.2005.09.016View ArticlePubMedGoogle Scholar
- Biron KK: Antiviral drugs for cytomegalovirus diseases. Antiviral Res 2006, 71: 154-163. 10.1016/j.antiviral.2006.05.002View ArticlePubMedGoogle Scholar
- Biron KK, Harvey RJ, Chamberlain SC, Good SS, Smith AA 3rd, Davis MG, Talarico CL, Miller WH, Ferris R, Dornsife RE, et al.: Potent and selective inhibition of human cytomegalovirus replication by 1263W94, a benzimidazole L-riboside with a unique mode of action. Antimicrob Agents Chemother 2002, 46: 2365-2372. 10.1128/AAC.46.8.2365-2372.2002PubMed CentralView ArticlePubMedGoogle Scholar
- Chou S: Cytomegalovirus UL97 mutations in the era of ganciclovir and maribavir. Rev Med Virol 2008, 18: 233-246. 10.1002/rmv.574View ArticlePubMedGoogle Scholar
- Wang LH, Peck RW, Yin Y, Allanson J, Wiggs R, Wire MB: Phase I safety and pharmacokinetic trials of 1263W94, a novel oral anti-human cytomegalovirus agent, in healthy and human immunodeficiency virus-infected subjects. Antimicrob Agents Chemother 2003, 47: 1334-1342. 10.1128/AAC.47.4.1334-1342.2003PubMed CentralView ArticlePubMedGoogle Scholar
- Michel D, Pavic I, Zimmermann A, Haupt E, Wunderlich K, Heuschmid M, Mertens T: The UL97 gene product of human cytomegalovirus is an early-late protein with a nuclear localization but is not a nucleoside kinase. J Virol 1996, 70: 6340-6346.PubMed CentralPubMedGoogle Scholar
- van Zeijl M, Fairhurst J, Baum EZ, Sun L, Jones TR: The human cytomegalovirus UL97 protein is phosphorylated and a component of virions. Virology 1997, 231: 72-80. 10.1006/viro.1997.8523View ArticlePubMedGoogle Scholar
- Prichard MN, Gao N, Jairath S, Mulamba G, Krosky P, Coen DM, Parker BO, Pari GS: A recombinant human cytomegalovirus with a large deletion in UL97 has a severe replication deficiency. J Virol 1999, 73: 5663-5670.PubMed CentralPubMedGoogle Scholar
- Baek MC, Krosky PM, He Z, Coen DM: Specific phosphorylation of exogenous protein and peptide substrates by the human cytomegalovirus UL97 protein kinase. Importance of the P+5 position. J Biol Chem 2002, 277: 29593-29599. 10.1074/jbc.M202312200View ArticlePubMedGoogle Scholar
- Kamil JP, Coen DM: Human cytomegalovirus protein kinase UL97 forms a complex with the tegument phosphoprotein pp65. J Virol 2007, 81: 10659-10668. 10.1128/JVI.00497-07PubMed CentralView ArticlePubMedGoogle Scholar
- Krosky PM, Baek MC, Jahng WJ, Barrera I, Harvey RJ, Biron KK, Coen DM, Sethna PB: The human cytomegalovirus UL44 protein is a substrate for the UL97 protein kinase. J Virol 2003, 77: 7720-7727. 10.1128/JVI.77.14.7720-7727.2003PubMed CentralView ArticlePubMedGoogle Scholar
- Baek MC, Krosky PM, Pearson A, Coen DM: Phosphorylation of the RNA polymerase II carboxyl-terminal domain in human cytomegalovirus-infected cells and in vitro by the viral UL97 protein kinase. Virology 2004, 324: 184-193. 10.1016/j.virol.2004.03.015View ArticlePubMedGoogle Scholar
- Kawaguchi Y, Matsumura T, Roizman B, Hirai K: Cellular elongation factor 1delta is modified in cells infected with representative alpha-, beta-, or gammaherpesviruses. J Virol 1999, 73: 4456-4460.PubMed CentralPubMedGoogle Scholar
- Marschall M, Marzi A, aus dem Siepen P, Jochmann R, Kalmer M, Auerochs S, Lischka P, Leis M, Stamminger T: Cellular p32 recruits cytomegalovirus kinase pUL97 to redistribute the nuclear lamina. J Biol Chem 2005, 280: 33357-33367. 10.1074/jbc.M502672200View ArticlePubMedGoogle Scholar
- Jault FM, Jault JM, Ruchti F, Fortunato EA, Clark C, Corbeil J, Richman DD, Spector DH: Cytomegalovirus infection induces high levels of cyclins, phosphorylated Rb, and p53, leading to cell cycle arrest. J Virol 1995, 69: 6697-6704.PubMed CentralPubMedGoogle Scholar
- Prichard MN, Sztul E, Daily SL, Perry AL, Frederick SL, Gill RB, Hartline CB, Streblow DN, Varnum SM, Smith RD, Kern ER: Human cytomegalovirus UL97 kinase activity is required for the hyperphosphorylation of retinoblastoma protein and inhibits the formation of nuclear aggresomes. J Virol 2008, 82: 5054-5067. 10.1128/JVI.02174-07PubMed CentralView ArticlePubMedGoogle Scholar
- Hume AJ, Finkel JS, Kamil JP, Coen DM, Culbertson MR, Kalejta RF: Phosphorylation of retinoblastoma protein by viral protein with cyclin-dependent kinase function. Science 2008, 320: 797-799. 10.1126/science.1152095View ArticlePubMedGoogle Scholar
- Felsani A, Mileo AM, Paggi MG: Retinoblastoma family proteins as key targets of the small DNA virus oncoproteins. Oncogene 2006, 25: 5277-5285. 10.1038/sj.onc.1209621View ArticlePubMedGoogle Scholar
- Sun A, Bagella L, Tutton S, Romano G, Giordano A: From G0 to S phase: a view of the roles played by the retinoblastoma (Rb) family members in the Rb-E2F pathway. J Cell Biochem 2007, 102: 1400-1404. 10.1002/jcb.21609View ArticlePubMedGoogle Scholar
- Chou S, Wechel LC, Marousek GI: Cytomegalovirus UL97 kinase mutations that confer maribavir resistance. J Infect Dis 2007, 196: 91-94. 10.1086/518514View ArticlePubMedGoogle Scholar
- Williams SL, Hartline CB, Kushner NL, Harden EA, Bidanset DJ, Drach JC, Townsend LB, Underwood MR, Biron KK, Kern ER: In vitro activities of benzimidazole D- and L-ribonucleosides against herpesviruses. Antimicrob Agents Chemother 2003, 47: 2186-2192. 10.1128/AAC.47.7.2186-2192.2003PubMed CentralView ArticlePubMedGoogle Scholar
- Chou S, Van Wechel LC, Lichy HM, Marousek GI: Phenotyping of cytomegalovirus drug resistance mutations by using recombinant viruses incorporating a reporter gene. Antimicrob Agents Chemother 2005, 49: 2710-2715. 10.1128/AAC.49.7.2710-2715.2005PubMed CentralView ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.